When facing thousands of listed company announcements every day, which ones should you read? What are the key points to take away from the dozens or hundreds of pages of material announcements? Are the many professional terms in the announcements bullish or bearish? Check out Caixin's "Quick Read Announcement" column, where our reporters across the country will provide you with accurate, fast and professional interpretations on the night of the announcement.

According to the Financial Association on November 26 (reporter Zhang Liangde), the well-established traditional chinese medicine company tj darentang (600329.SH) is changing leadership. The current chairman Zhang Mingrui has resigned due to job changes, and current general manager Wang Lei will soon take over as chairman. In this regard, relevant personnel of the company told Financial Association reporters that, "President Zhang originally held the president position at the controlling shareholder, now he is resigning from the position of chairman of the listed company."

Regarding the company's future development global strategy, the aforementioned individual stated, "will not change."

The announcement released by tj darentang tonight shows that Zhang Mingrui has also resigned from the positions of company director and chairman of the strategy committee. Regarding Zhang Mingrui's resignation, some small and medium shareholders expressed: there had been some signs earlier. At last week's temporary shareholders' meeting, when faced with a shareholder's question, Wang Lei, who was asked to respond, answered multiple shareholder inquiries.

Zhang Mingrui is the first chairman after tj darentang completed its mixed-ownership reform, having a considerable impact on the company's development in the past two years. From 2021 to 2023, the company net income has maintained double-digit growth.

The company announcement stated that during her tenure as chairman, Zhang Mingrui led the board of directors to focus on the company's "1+5" strategy; keeping a close eye on corporate governance and promoting transformation optimization; leading the company to focus on the market, refreshing the brand, and leading innovation; committed to enhancing tj darentang's brand power, innovation capacity, product strength, and service capability; formulating the company's "three core nine wings" product strategy, continuously strengthening and expanding around core main products; tj darentang's development has entered the fast lane of high-quality development. The board of directors expresses heartfelt gratitude to Ms. Zhang Mingrui for her significant contributions to the company!

After Zhang Mingrui's resignation, the company held its ninth board of directors meeting for 2024 via communication on the 26th, and approved the proposal to elect director Wang Lei as chairman of the company. Regarding Wang Lei's succession to the position of chairman, some small and medium shareholders told reporters that President Wang is also a veteran of the company and can be asked about the operational ideas during the next company visit.

Wang Lei has indeed been a "veteran" at tj darentang usd, having worked there since 1993 when it was known as zhongxin pharmaceutical. She has successively held positions at tj darentang pharmaceutical factory, the planning department of zhongxin pharmaceutical's chinese patent medicine division, the industrial department of zhongxin pharmaceutical, le ren tang pharmaceutical factory, jingwanhong pharmaceutical, and tianjin pharmaceutical group. She has served as a supervisor, deputy general manager, general manager, and director at zhongxin pharmaceutical, and since August 2022, she has been the general manager of tj darentang.

At the same time, after Zhang Mingrui resigned from the director position, the company also filled the vacancy on the board of directors. The company’s supervisor, Xing Jianhua, resigned from his position as supervisor and was nominated by the board of directors as a candidate for director. The announcement shows that Xing Jianhua has been the chief financial officer (CFO) of tj darentang's controlling shareholder, tianjin pharmaceutical group co., ltd. since May 2021.

The company's board of supervisors also nominated another financial professional, Xie Xi, as a new candidate for supervisor. Previously, he had held positions such as accountant in tj darentang's finance department, assistant to the finance department manager, securities affairs representative, deputy finance department manager, finance department manager, and deputy general manager of the finance department of tianjin pharmaceutical group.